SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SAN FRANCISCO, March 17, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in Stemline Therapeutics, Inc. (NASDAQ:STML) of the April 4, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased or otherwise acquired securities of Stemline (1) pursuant to Stemline’s secondary public offering on or about January 20, 2017 or (2) on the open market between January 6, 2017 and February 1, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/STML
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On February 2, 2017, TheStreet published an article entitled “Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money.” TheStreet reported that investors who bought into a $45 million Stemline Therapeutics stock offering on January 19, 2017 were not told that one day prior to the financing, a cancer patient in a clinical trial died from a severe side effect, a type of low blood pressure, tied to the Company’s SL-401 drug.
This news drove the price of Stemline shares down over 42% on February 2, 2017.
“A cancer patient’s death occurring from Stemline SL-401 related side effects is a tragic event and is a fact reasonable investors would want to know about,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Stemline should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
